Intensifying Competition and Loss of Competitive Advantage in Cancer Treatment
First written in FY2021. 1 of 2 entries say "Restated". Latest entry: FY2022.
The whole theme swung hardest in 2025: 4 of 8 companies on the "Worse" side.
8 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「Our development pipeline is focused on cancer treatment, an area considered particularly competitive, and the competitive advantage of our products under development may decline depending on the results of research into new drugs and other products or their development outcomes.」
The company continues to identify the risk of intensifying competition in cancer treatment and declining competitive advantage due to competing new drugs and other products. - FY2021First statedAnnual report
「Our development pipeline is focused on cancer treatment, an area considered particularly competitive, and the competitive advantage of our products under development may decline depending on the results of research into new drugs and other products or their development outcomes.」
The company identifies new drug development by competitors and research institutions, as well as post-launch sales competition, as risks.